Do you know what they contain? Match the brand names in Section I with the generic ingredients in Section II.
Section I
_____ 1. Jalyn (GlaxoSmithKline)
_____ 2. Gelnique 3% (Watson Pharmaceuticals)
_____ 3. Injectafer (Luitpold Pharmaceuticals)
_____ 4. Myrbetriq (Astellas Pharma U.S.)
Section II
a. mirabegron.
This beta3-adrenergic agonist is indicated to treat overactive bladder (OAB). It's taken orally once daily with or without food. Because BP increases may occur, this medication shouldn't be used in patients with uncontrolled hypertension.
b. oxybutynin chloride gel 3%.
A topical treatment indicated to treat OAB, this drug is a muscarinic receptor antagonist (anticholinergic) causing bladder smooth muscle relaxation. Teach patients to apply each dose as directed to clean, dry, intact skin of the abdomen, upper arms/shoulders, or thighs.
c. dutasteride/tamsulosin.
This product is a combination of two medications indicated to treat symptomatic benign prostatic hyperplasia. Dutasteride inhibits the conversion of testosterone to dihydrotestosterone, and tamsulosin improves urine flow by relaxing smooth muscles in the bladder neck and prostate. Tell patients to take one capsule daily, 30 minutes after the same meal. This medication shouldn't be handled by women who are pregnant or may become pregnant.
d. ferric carboxymaltose injection.
This injectable iron preparation is indicated for iron deficiency anemia in adults with chronic kidney disease who aren't on dialysis and who can't tolerate oral iron preparations. Two doses must be administered 7 days apart to complete the dosing regimen; repeat doses are administered if iron deficiency reoccurs. Monitor patients for hypersensitivity reactions for up to 30 minutes after each dose.
Resources available on request.
ANSWERS: 1-c, 2-b, 3-d, 4-a